MarketPR
Novo's Wegovy Pill Still Leads the GLP-1 Pill Market as Lilly's Foundayo Launches Novo Nordisk's Wegovy pill remains a top choice among Americans for weight loss even after the launch of Foundayo, Eli Lilly's GLP-1 pill, according to MarketWatch.
The two drugmakers are now competing directly in the oral GLP-1 weight-loss market.
Novo Nordisk (NVO) markets the Wegovy pill, while Eli Lilly (LLY) has entered the same segment with the recent launch of its own GLP-1 pill, Foundayo.
Per the source, Wegovy's pill has held its standing as a leading option among American consumers despite the arrival of a direct competitor.
Keep reading